Cardiol Therapeutics Inc. (CRDL.TO)
CAD 1.96
(0.51%)
CAD 1.96
(0.51%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -25.18 Thousand | -27.22 Million | -23.55 Million | -9.18 Million | -11.38 Million | -10.89 Million |
| Net Income | -28.12 Thousand | -30.93 Million | -31.63 Million | -20.64 Million | -13.68 Million | -15.89 Million |
| Depreciation & Amortization | 248.36 | 219.9 Thousand | 220.42 Thousand | 229.53 Thousand | 150.57 Thousand | 91.49 Thousand |
| Deferred income taxes | -1.59 Million | - | -4.91 Million | - | - | 7.88 Million |
| Stock-based compensation | 4173.21 | 5.01 Million | 8.49 Million | 2.76 Million | 3.26 Million | 1.65 Million |
| Change in working capital | 746.80 | 5.74 Million | 76.52 Thousand | 8.31 Million | -1.62 Million | -5.2 Million |
| Other non-cash items | -2220.51 | -7.27 Million | 4.2 Million | 144.99 Thousand | 507.74 Thousand | 574.86 Thousand |
| Investing Cash Flow | -64.31 | -74.7 Thousand | -12.91 Thousand | -40.6 Thousand | -424.3 Thousand | -13.79 Thousand |
| Investments in PPE | -64.31 | -74.7 Thousand | -12.91 Thousand | -40.6 Thousand | -424.3 Thousand | -13.79 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | -55.38 | -53.93 Thousand | 93.43 Million | 16.29 Million | 2.02 Million | 25.28 Million |
| Debt repayment | -55.38 | -53.93 Thousand | -51.91 Thousand | -50.47 Thousand | -20.18 Thousand | -12.06 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 84.08 Million | 17.25 Million | 1.66 Million | 14.23 Million |
| Other Financing Activities | -55.37 Thousand | -53.93 | 9.4 Million | -904.51 Thousand | 382.15 Thousand | 11.04 Million |
| Accounts receivables | 67.18 | -144.18 Thousand | -59.94 Thousand | 707.94 Thousand | -467.08 Thousand | -359.03 Thousand |
| Accounts payables | -1.29 Million | 4.47 Million | 2.39 Million | -707.94 Thousand | 467.08 Thousand | 1.96 Million |
| Inventory | - | -4.47 Million | 17.96 Thousand | 1.1 Million | 142.57 Thousand | -6345.53 |
| Other working capital | 679.62 | 5.89 Million | -2.27 Million | 7.21 Million | -1.76 Million | -7.16 Million |
| Cash at beginning of period | 59.46 Thousand | 83.89 Million | 14.02 Million | 6.95 Million | 16.73 Million | 2.35 Million |
| Cash at end of period | 34.93 Thousand | 59.46 Million | 83.89 Million | 14.02 Million | 6.95 Million | 16.73 Million |
| Capital Expenditure | -64.31 | -74.7 Thousand | -12.91 Thousand | -40.6 Thousand | -424.3 Thousand | -13.79 Thousand |
| Effect of forex changes on cash | 762.04 | 2.91 Million | -11.12 Thousand | -56.02 Thousand | - | - |
| Net cash flow / Change in cash | -24.53 Thousand | -24.42 Million | 69.87 Million | 7.06 Million | -9.77 Million | 14.37 Million |
| Free Cash Flow | -25.24 Thousand | -27.29 Million | -23.56 Million | -9.22 Million | -11.8 Million | -10.9 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -6.59 Million | -9.17 Million | -28.12 Million | -7.63 Million | -5.93 Million | -7.47 Million |
| Depreciation & Amortization | 61.9 Thousand | 61.62 Thousand | 248.35 Thousand | 66.76 Thousand | 64.89 Thousand | 58.49 Thousand |
| Deferred income taxes | - | - | -1.59 Million | 725.46 Thousand | 575.32 Thousand | 10.36 Thousand |
| Stock-based compensation | 1.8 Million | 902.1 Thousand | 4173.21 | 1012.75 | 2.05 Million | 666.4 Thousand |
| Change in working capital | 782.03 Thousand | -31.03 Thousand | -545.87 Thousand | 1.53 Million | -181.28 Thousand | 1.38 Million |
| Other non-cash items | 442.09 Thousand | 1.57 Million | 4.83 Million | -1.15 Million | 5937.00 | 1376.00 |
| Investing Cash Flow | -3800.00 | -3460.00 | -64.31 Thousand | -10.7 Thousand | -5577.00 | -3891.00 |
| Investments in PPE | -3800.00 | -3460.00 | -64.31 Thousand | -10.7 Thousand | -5577.00 | -3891.00 |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 78.08 Thousand | 76.35 Thousand | -55.37 Thousand | -13.84 Thousand | -13.84 Thousand | -13.84 Thousand |
| Debt repayment | -9229.00 | -13.84 Thousand | -55.38 | -13.84 | -13.84 Thousand | -13.84 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 87.31 Thousand | 90.19 Thousand | - | - | - | - |
| Other Financing Activities | -9229.00 | 90.20 | - | - | - | -13.84 |
| Accounts receivables | 74.68 Thousand | -37.23 Thousand | 200.32 Thousand | 9723.00 | 10.35 Thousand | 9482.00 |
| Accounts payables | 578.26 Thousand | 811.7 Thousand | -1.29 Million | 850.27 Thousand | 23.01 Thousand | 444.93 Thousand |
| Inventory | - | - | - | - | -23.01 Thousand | -444.93 Thousand |
| Other working capital | 129.09 Thousand | -805.5 Thousand | 546.47 Thousand | 678.38 Thousand | -191.63 Thousand | 1.37 Million |
| Cash at beginning of period | 28.57 Million | 34.86 Million | 59.4 Million | 40.47 Million | 44.94 Million | 49.46 Million |
| Cash at end of period | 24.02 Million | 28.57 Million | 34.86 Million | 34.86 Million | 40.54 Million | 44.94 Million |
| Capital Expenditure | -3800.00 | -3460.00 | -64.31 Thousand | -10.7 Thousand | -5577.00 | -3891.00 |
| Effect of forex changes on cash | 149.68 Thousand | 491.09 Thousand | 762.04 | 880.95 | -968.2 Thousand | 846.53 Thousand |
| Net cash flow / Change in cash | -4.55 Million | -6.29 Million | -24.53 Million | -5.6 Million | -4.4 Million | -4.52 Million |
| Free Cash Flow | -4.77 Million | -6.92 Million | -25.24 Million | -6.47 Million | -3.42 Million | -5.35 Million |
0VAG
THS
KVIKA
FMAN
RATEGAIN
KSCP